Analysts Set Target Price for Icon Plc at $203.81 Amid Mixed Ratings

Shares of Icon Plc (NASDAQ:ICLR) have received an average rating of “Moderate Buy” from analysts at twenty research firms currently covering the stock, according to MarketBeat. This assessment includes twelve analysts recommending a hold, six suggesting a buy, and two endorsing a strong buy rating for the company. The average target price set for Icon over the next year stands at $199.87, reflecting varied perspectives among industry analysts.

Several firms have recently updated their evaluations of Icon. On December 29, Weiss Ratings reiterated its “hold (c)” rating in a research note. Earlier, on December 15, Bank of America downgraded Icon from a “buy” to a “neutral” rating, establishing a price objective of $195.00. Meanwhile, Mizuho set a higher target price of $216.00 in its report on January 9. Leerink Partners reaffirmed an “outperform” rating on January 5, while Cowen reiterated a hold rating on October 24.

Current Stock Performance and Financial Indicators

On Monday, shares of Icon opened at $184.77. The company maintains a debt-to-equity ratio of 0.31, with both a quick ratio and current ratio of 1.06. With a market capitalization of $14.92 billion, Icon’s price-to-earnings ratio is 25.00, and its price/earnings to growth ratio stands at 3.86. The stock has experienced a 52-week low of $125.10 and a high of $211.00. As of now, the company’s 50-day simple moving average is $178.31, while its 200-day simple moving average is $173.69.

About Icon Plc

Icon plc is a global leader in providing outsourced drug development and clinical research services aimed at the pharmaceutical, biotechnology, and medical device sectors. The company collaborates with clients throughout all stages of the product lifecycle. Its expertise spans protocol design, trial execution, and regulatory compliance across a diverse range of therapeutic areas.

Icon’s extensive service offerings include clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, as well as laboratory sciences and specialized analytical solutions. This comprehensive approach positions Icon as a key player in the evolving landscape of medical research and development.

As investors and analysts continue to monitor Icon’s performance and market positioning, the outlook remains dynamic, with various ratings reflecting ongoing assessments of the company’s potential within the industry.